Daily Archives: Apr 17, 2018

    El nombre del nuevo mandatario de Cuba sólo se conocerá en la sesión del jueves, anuncian medios oficiales

    Por: EFE

    La Asamblea Nacional de Cuba inició este miércoles la sesión constitutiva de una nueva legislatura, de donde saldrá elegido el sucesor de Raúl Castro en la presidencia de Cuba, nombre que se divulgará el jueves.

    Castro y el vicepresidente primero Miguel Díaz-Canel Bermúdez entraron juntos a la sesión en el salón del Palacio de las Convenciones de La Habana con una cerrada ovación de los 605 diputados. Díaz-Canel, de 57 años, es el virtual sustituto de Castro en la presidencia del Consejo de Estado.

    La reunión, transmitida por la señal oficial de TV, se inició con la acreditación y el juramento de los diputados elegidos por la población en los comicios de marzo. Ellos luego elegirán a su mesa directiva. El presidente del Parlamento saliente es Esteban Lazo, de 74 años, quien ocupó el cargo desde 2013. No se descarta que pueda ser reelecto.

    Posteriormente, según el programa difundido por los medios oficiales, una comisión de candidatura presentará a los diputados la nómina para los 31 miembros del Consejo de Estado, incluidos el presidente, vicepresidente primero, cinco vicepresidentes, y otros miembros. La votación de la Asamblea será este mismo miércoles.

    No obstante, el nombre del presidente del Consejo de Estado, sucesor de Raúl Castro, sólo se conocerá en la sesión del jueves, anunciaron los medios oficiales.

    Why is the United States ignoring one of the most effective strategies against the Opioid Crisis?

    By Maximilian Eyle

    In the 1990s, Syringe Exchange Programs (SEPs) became a hotly debated harm reduction strategy. The tactic of providing people who inject drugs with sterile syringes was originally developed in the Netherlands in 1983, and was eventually adopted by many other countries to combat the spread of HIV/AIDS and other infections. For many years, SEPs faced strong criticism in the USA by those claiming it enabled drug use, though the studies examining its impact showed that this was a fallacy. The practice significantly reduces the transmission of disease and infection via shared needles. Today, its efficacy as a harm reduction tool has long been proven though many legal barriers still prevent its application in many U.S. states. We are watching history repeat itself along the topic of Safe Injection Facilities (SIFs).

    A Safe Injection Facility is a clean, safe environment where users can inject their own drugs under the supervision of clinical staff. As we face public health issues in the United States, we often forget that other countries have faced the same problems and in many cases have developed effective strategies to overcome them. In response to an epidemic of opioid abuse in Europe, the concept of SIFs was developed to facilitate low-risk, hygienic drug consumption, and reduce risk of fatal overdose and transmission of HIV and HCV along with other infections. The service also puts users in touch with social services, drug treatment services, and mental health services while reducing public drug use and unsafe needle disposal.

    Opiate overdose is now the leading cause of death for people under 50 years in America, with a total of 64,000 deaths nationwide in 2016. The CDC reports that there are an average of 115 unintended overdose deaths per day in the US. Last year, 91 people died from opioid overdoses in Onondaga County alone. How many unnecessary deaths until the US joins Canada, Europe, and Australia with the commensurate pragmatic and effective public health policy of Safe Injection Facilities?

    SIFs vary in the details of their operation, but most follow a similar format: users can inject under clinical supervision with clean equipment. After injection, they usually go to a post-injection room to be treated for any wounds or infections, seek counseling, and receive other services. Palliative care is also available (food, showers, clothes, and laundry), and registered nurses, trained peer workers, and addiction counselors are available as needed. If an emergency occurs, the presence of trained medical staff and a well-equipped facility prevents it from becoming a fatality.

    Though the first Safe Injection Facilities emerged in central Europe over 30 years ago, the practice continues to face strong resistance in the United States today – despite overwhelming evidence demonstrating its efficacy. Currently, there are nearly 100 SIFs in Canada, Australia,

    and Europe. None exist in the United States, though some cities are beginning to consider the idea. The “Opioid Epidemic” in our country has become a national issue, but our interest in exploring new approaches to harm reduction remains stubbornly absent. In her article, “How Much Evidence Is Enough?”, Professor Lisa Maher cites the large body of peer reviewed research demonstrating that SIFs reduce overdose fatalities, prevent needle sharing and unsafe syringe disposal, increase participation in treatment programs, and have not caused increases in drug use or crime. Furthermore, they are shown to be well accepted by the communities in which they exist due to the positive effects resulting from their presence. With this information in front of us, it seems unthinkable that SIFs continue to face powerful resistance in the United States.

    By continuing to threaten people who inject drugs with arrest, we only add new elements of danger and difficulty to their lives. Heroin has been illegal since the passage of the Harrison Act in 1914 and yet continues to be a significant public health problem over 100 years later. This is further evidence that we are in desperate need of a new approach to this area of drug policy. Safe Injection Facilities keep people with addictions out of the criminal justice system and allow them to be treated more humanely by placing an emphasis on their health and well-being.

    The United States District Court for the Western District of New York is inviting applications for expansion of the Alternative Dispute Resolution Program Mediator Panel.  Attorneys and non-attorneys with relevant experience may submit an application, resume, and letter of interest to:

    WDNY ADR Program
    Robert H. Jackson United States Courthouse
    2 Niagara Square
    Buffalo, NY 14202
    or
    adrprogram@nywd.uscourts.gov

    Applications are located on the ADR Program Website:
    http://www.nywd.uscourts.gov/alternative-dispute-resolution

    The deadline for submission is May 31, 2018.

    Informational meetings regarding the ADR Program will be offered at the
    US District Court in Buffalo, 2 Niagara Square on Wednesday, May 2, 2018 at 5:00 p.m. and at
    US District Court in  Rochester, 100 State Street, on Thursday, May 3, 2018 at 5:00 p.m.

    If you have any questions, please contact:
    Barry Radlin, ADR Program Administrator at (716) 551-1511
     Amanda Williams, ADR Program Law Clerk at (716) 551-1817

     

    STAY CONNECTED

    WP Facebook Auto Publish Powered By : XYZScripts.com